Omeros’ (OMER) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Omeros (NASDAQ:OMER) in a research note released on Thursday,Benzinga reports. D. Boral Capital currently has a $36.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on OMER. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Rodman & Renshaw started coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 4.5 %

NASDAQ:OMER opened at $9.18 on Thursday. Omeros has a 1-year low of $2.61 and a 1-year high of $13.60. The firm has a market capitalization of $531.98 million, a price-to-earnings ratio of -3.97 and a beta of 1.98. The stock has a fifty day simple moving average of $9.30 and a 200 day simple moving average of $6.74.

Institutional Investors Weigh In On Omeros

Several hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new stake in shares of Omeros during the 3rd quarter worth about $80,000. Charles Schwab Investment Management Inc. raised its stake in shares of Omeros by 4.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. HighTower Advisors LLC raised its stake in shares of Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 4,000 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after purchasing an additional 3,839 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.